Chemical Reviews pubs.acs.
org/CR Review
(35) Sahin, U.; Kariko, K.; Tureci, O. mRNA-Based Therapeutics– (59) Joyce, H.; McCann, A.; Clynes, M.; Larkin, A. Influence of
Developing a New Class of Drugs. Nat. Rev. Drug Discovery 2014, 13, Multidrug Resistance and Drug Transport Proteins on Chemotherapy
759−780. Drug Metabolism. Expert Opin. Drug Metab. Toxicol. 2015, 11, 795−
(36) Morrison, C. Constrained Peptides’ Time to Shine? Nat. Rev. 809.
Drug Discovery 2018, 17, 531−533. (60) Zahreddine, H.; Borden, K. Mechanisms and Insights into Drug
(37) Mullard, A. First Targeted Protein Degrader Hits the Clinic. Resistance in Cancer. Front. Pharmacol. 2013, 4, 28.
Nat. Rev. Drug Discovery 2019, 18, 237−239. (61) Sampath, D.; Cortes, J.; Estrov, Z.; Du, M.; Shi, Z.; Andreeff,
(38) Bennett, G.; Harrison, H.; Campbell, S.; Teufel, D.; Langford, M.; Gandhi, V.; Plunkett, W. Pharmacodynamics of Cytarabine Alone
G.; Watt, A.; Bonny, C. Development of BT1718, a Bicycle Drug and in Combination with 7-hydroxystaurosporine (UCN-01) in AML
Conjugate (BDC) Targeting MT1-MMP for Treatment of Solid Blasts In Vitro and During a Clinical Trial. Blood 2006, 107, 2517−
Tumours. Eur. J. Cancer 2016, 69, S21. 2524.
(39) Crunkhorn, S. RNA-based Therapeutics: Increasing Efficacy. (62) Momparler, R. L. Biochemical Pharmacology of Cytosine
Nat. Rev. Drug Discovery 2017, 16, 680. Arabinoside. Med. Pediatr. Oncol. 1982, 10, 45−48.
(40) Lawler, S. E.; Speranza, M.-C.; Cho, C.-F.; Chiocca, E. A. (63) Shelton, J.; Lu, X.; Hollenbaugh, J. A.; Cho, J. H.; Amblard, F.;
Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncology Schinazi, R. F. Metabolism, Biochemical Actions, and Chemical
2017, 3, 841−849. Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.
(41) The Cost of Sequencing a Human Genome. National Human Chem. Rev. 2016, 116, 14379−14455.
Genome Research Institute. https://www.genome.gov/about- (64) Manikandan, P.; Nagini, S. Cytochrome P450 Structure,
genomics/fact-sheets/Sequencing-Human-Genome-cost (accessed Function and Clinical Significance: A Review. Curr. Drug Targets
2020-03). 2018, 19, 38−54.
(42) Myers, M. B. Targeted Therapies with Companion Diagnostics (65) Meijer, C.; Mulder, N. H.; Timmer-Bosscha, H.; Sluiter, W. J.;
in the Management of Breast Cancer: Current Perspectives. Meersma, G. J.; de Vries, E. G. E. Relationship of Cellular Glutathione
Pharmacogenomics Pers. Med. 2016, 9, 7−16. to the Cytotoxicity and Resistance of Seven Platinum Compounds.
(43) Morgan, R. A. Human Tumor Xenografts: The Good, the Bad, Cancer Res. 1992, 52, 6885−6889.
and the Ugly. Mol. Ther. 2012, 20, 882−884. (66) Kelley, S.; Basu, A.; Teicher, B.; Hacker, M.; Hamer, D.; Lazo,
(44) Verma, M. Personalized Medicine and Cancer. J. Pers. Med. J. Overexpression of Metallothionein Confers Resistance to
2012, 2, 1−14. Anticancer Drugs. Science 1988, 241, 1813−1815.
(45) Luo, J.; Solimini, N. L.; Elledge, S. J. Principles of Cancer (67) Wood, K. C. Mapping the Pathways of Resistance to Targeted
Therapy: Oncogene and Non-Oncogene Addiction. Cell 2009, 136, Therapies. Cancer Res. 2015, 75, 4247−4251.
823−837. (68) Kandoth, C.; McLellan, M. D.; Vandin, F.; Ye, K.; Niu, B.; Lu,
(46) Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell C.; Xie, M.; Zhang, Q.; McMichael, J. F.; Wyczalkowski, M. A.; et al.
Mutational Landscape and Significance Across 12 Major Cancer
2000, 100, 57−70.
(47) Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Types. Nature 2013, 502, 333−339.
(69) Sutto, L.; Gervasio, F. L. Effects of Oncogenic Mutations on the
Generation. Cell 2011, 144, 646−674.
Conformational Free-Energy Landscape of EGFR Kinase. Proc. Natl.
(48) Robey, R. W.; Pluchino, K. M.; Hall, M. D.; Fojo, A. T.; Bates,
Acad. Sci. U. S. A. 2013, 110, 10616−10621.
S. E.; Gottesman, M. M. Revisiting the Role of ABC Transporters in
(70) Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.;
Multidrug-Resistant Cancer. Nat. Rev. Cancer 2018, 18, 452−464.
Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; et al. Discovery of a
(49) Gottesman, M. M.; Pastan, I. H. The Role of Multidrug
Selective Inhibitor of Oncogenic B-Raf kinase with Potent
Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication
Antimelanoma Activity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105,
Exploring Expression of the MDR1 (P-glycoprotein) Gene. J. Natl.
3041−3046.
Cancer Inst. 2015, 107, djv222. (71) Marcucci, G.; Perrotti, D.; Caligiuri, M. A. Understanding the
(50) Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein Inhibition as a Molecular Basis of Imatinib Mesylate Therapy in Chronic
Therapeutic Approach for Overcoming Multidrug Resistance in Myelogenous Leukemia and the Related Mechanisms of Resistance.
Cancer: Current Status and Future Perspectives. Curr. Cancer Drug Clin. Cancer Res. 2003, 9, 1248−1252.
Targets 2013, 13, 326−346. (72) Solomon, B.; Wilner, K. D.; Shaw, A. T. Clin. Pharmacol. Ther.
(51) Ni, W.; Chen, W.; Lu, Y. Emerging Findings into Molecular 2013, 95, 15−23.
Mechanism of Brain Metastasis. Cancer Med. 2018, 7, 3820−3833. (73) Van Der Steen, N.; Giovannetti, E.; Pauwels, P.; Peters, G. J.;
(52) Wang, Q.; Rager, J. D.; Weinstein, K.; Kardos, P. S.; Dobson, G. Hong, D. S.; Cappuzzo, F.; Hirsch, F. R.; Rolfo, C. Current Status of
L.; Li, J.; Hidalgo, I. J. Evaluation of the MDR-MDCK Cell Line as a Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-
Permeability Screen for the Blood-Brain Barrier. Int. J. Pharm. 2005, Small Cell Lung Cancer. J. Thorac. Oncol. 2016, 11, 1423−1432.
288, 349−359. (74) Bischoff, R.; Schluter, H. Amino Acids: Chemistry, Function-
(53) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. ality and Selected Non-Enzymatic Post-Translational Modifications. J.
Multiparameter Optimization Desirability: Application in Drug Proteomics 2012, 75, 2275−2296.
Discovery. ACS Chem. Neurosci. 2016, 7, 767−775. (75) Bissantz, C.; Kuhn, B.; Stahl, M. Medicinal Chemist’s Guide to
(54) Summerfield, S. G.; Zhang, Y.; Liu, H. Examining the Uptake of Molecular Interactions. J. Med. Chem. 2010, 53, 5061−5084.
Central Nervous System Drugs and Candidates across the Blood- (76) Mian, A. A.; Schull, M.; Zhao, Z.; Oancea, C.; Hundertmark,
Brain Barrier. J. Pharmacol. Exp. Ther. 2016, 358, 294−305. A.; Beissert, T.; Ottmann, O. G.; Ruthardt, M. The Gatekeeper
(55) Gupta, M.; Lee, H. J.; Barden, C. J.; Weaver, D. F. The Blood- Mutation T315I Confers Resistance Against Small Molecules by
Brain Barrier (BBB) Score. J. Med. Chem. 2019, 62, 9824−9836. Increasing or Restoring the ABL-Kinase Activity Accompanied by
(56) Wang, Y.; Gallagher, E.; Jorgensen, C.; Troendle, E. P.; Hu, D.; Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-
Searson, P. C.; Ulmschneider, M. B. An Experimentally Validated Of-Function Mutants of BCR/ABL. Leukemia 2009, 23, 1614−1621.
Approach to Calculate the Blood-Brain Barrier Permeability of Small (77) Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the
Molecules. Sci. Rep. 2019, 9, 6117. ″Gatekeeper Door″: Exploiting the Active Kinase Conformation. J.
(57) Davis, M. E. Glioblastoma: Overview of Disease and Med. Chem. 2010, 53, 2681−2694.
Treatment. Clin. J. Oncol. Nurs. 2016, 20, S2−S8. (78) Barouch-Bentov, R.; Sauer, K. Mechanisms of Drug Resistance
(58) Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug Resistance in Kinases. Expert Opin. Invest. Drugs 2011, 20, 153−208.
in Cancer: Role of ATP-Dependent Transporters. Nat. Rev. Cancer (79) Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.;
2002, 2, 48−58. Zakowski, M. F.; Chiang, A.; Yang, G.; Ouerfelli, O.; Kris, M. G.; et al.
AS https://dx.doi.org/10.1021/acs.chemrev.0c00383
Chem. Rev. XXXX, XXX, XXX−XXX
